



## New Perspectives on Targeted Therapy in Ovarian Cancer

Guest Editor:

**Prof. Dr. Appu Rathinavelu**

1. Rumbaugh-Goodwin Institute for Cancer Research, Nova Southeastern University, Fort Lauderdale, FL 33314, USA  
2. College of Pharmacy, Health Professions Division, Nova Southeastern University, Fort Lauderdale, FL 33314, USA

Deadline for manuscript submissions:

**closed (30 April 2021)**

### Message from the Guest Editor

Dear Colleagues,

Ovarian cancer is the second most common and the most lethal gynecologic malignancy among women in the western world. Late detection of ovarian cancer is related to the lack of early warning symptoms, and, as a consequence, about 70% of ovarian cancers are diagnosed at an advanced stage with a bad prognosis. It is difficult to cure late-stage ovarian cancer; however, recent advancements in ovarian cancer treatments are helping to make it a manageable chronic disease. This is mostly due to the current progress with surgical technology, contemporary regimens of systemic treatment, as well as the introduction of new drugs. However, many new drugs and treatment strategies are under development. Some of the examples of new drugs under development for ovarian cancer include anti-angiogenic factors, inhibitors of growth factor signaling, polyADP-ribose polymerase inhibitors, folate receptor inhibitors, and DNA repair strategies. In addition, immunotherapeutic approaches are also being tested.

In this Special Issue of *Medicina*, we will discuss the current advances in therapy for ovarian cancer, highlight some of the new therapeutic approaches, and their present status.





# medicina

IMPACT  
FACTOR  
2.4

Indexed in:  
PubMed

CITESCORE  
3.3

an Open Access Journal by MDPI

## Editor-in-Chief

### Prof. Dr. Edgaras Stankevičius

Medical Academy, Lithuanian  
University of Health Sciences,  
Kaunas, Lithuania

## Message from the Editor-in-Chief

You are invited to contribute a research article or a comprehensive review for consideration and publication in *Medicina* (ISSN: 1648-9144). *Medicina* is an open access, peer-reviewed scientific journal that publishes original articles, critical reviews, research notes, and short communications on medicine. The scientific community and the general public can access the content free of charge as soon as it is published.

## Author Benefits

**Open Access:** free for readers, with article processing charges (APC) paid by authors or their institutions.

**High Visibility:** indexed within Scopus, SCIE (Web of Science), PubMed, MEDLINE, PMC, and other databases.

**Journal Rank:** JCR - Q1 (Medicine, General and Internal) / CiteScore - Q1 (General Medicine)

## Contact Us

---

Medicina Editorial Office  
MDPI, St. Alban-Anlage 66  
4052 Basel, Switzerland

Tel: +41 61 683 77 34  
[www.mdpi.com](http://www.mdpi.com)

[mdpi.com/journal/medicina](http://mdpi.com/journal/medicina)  
[medicina@mdpi.com](mailto:medicina@mdpi.com)